Molecular Templates Inc (OQ:MTEM)

Dec 09, 2019 10:00 am ET
Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics,...
Nov 26, 2019 08:00 am ET
Molecular Templates to Present at Two December Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
Nov 21, 2019 07:00 am ET
Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 20, 2019 04:01 pm ET
Molecular Templates, Inc. Announces Proposed Public Equity Offering
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 18, 2019 07:00 am ET
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop...
Nov 14, 2019 08:00 am ET
Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111
Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with its partner Molecular Templates (Nasdaq: MTEM). This Phase I first-in-human...
Nov 12, 2019 05:00 pm ET
Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are...
Nov 07, 2019 04:27 pm ET
Molecular Templates Hosting Analyst & Investor Meeting
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for...
Sep 23, 2019 04:30 pm ET
Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for...
Aug 12, 2019 04:30 pm ET
Molecular Templates, Inc. Reports Second Quarter 2019 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are...
Jun 17, 2019 08:00 am ET
Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38
Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic...
May 14, 2019 04:30 pm ET
Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
May 13, 2019 04:01 pm ET
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Apr 25, 2019 10:12 am ET
The Judge Group Named a Winner of the Delaware Valley 2019 Top Workplaces Award by Philadelphia Media Network
The Judge Group, a leading global professional services firm, has been awarded a 2019 Top Workplaces honor by Philadelphia Media Network. The award is based solely on employee feedback gathered through a third-party survey administered by research...
Apr 22, 2019 08:00 am ET
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Apr 10, 2019 09:10 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Cousins Properties, Versum Materials, Meritor, Ardelyx, Molecular Templates, and Talend S.A — New Research Emphasizes Economic Growt
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cousins Properties Incorporated (NYSE:CUZ), Versum Materials Inc. (NYSE:VSM),...
Apr 02, 2019 07:00 am ET
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2019 Highlight Evolution of ETB Platform
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Mar 28, 2019 04:30 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Mar 28, 2019 08:00 am ET
Molecular Templates Announces Initiation of Phase II Monotherapy Study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Mar 05, 2019 04:30 pm ET
Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Feb 27, 2019 05:00 pm ET
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2019
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Feb 19, 2019 04:30 pm ET
Molecular Templates Appoints Roger J. Waltzman, M.D., as Chief Medical Officer
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Feb 12, 2019 08:30 am ET
New Research Coverage Highlights Overstock, Regeneron Pharmaceuticals, Molecular Templates, The Ensign Group, Limoneira, and Primo Water — Consolidated Revenues, Company Growth, and Expectations for 2
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Overstock.com, Inc. (NASDAQ:OSTK), Regeneron Pharmaceuticals, Inc....
Nov 26, 2018 04:30 pm ET
Molecular Templates to Present at the Evercore ISI and BMO Healthcare Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Nov 13, 2018 04:30 pm ET
Molecular Templates, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 09, 2018 08:00 am ET
Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
Molecular Templates, Inc., (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Oct 16, 2018 07:35 am ET
New Research Coverage Highlights Amtech, Neos Therapeutics, FTD Companies, John B. Sanfilippo & Son, Molecular Templates, and Aevi Genomic Medicine — Consolidated Revenues, Company Growth, and Expecta
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amtech Systems, Inc. (NASDAQ:ASYS), Neos Therapeutics, Inc. (NASDAQ:NEOS),...
Sep 26, 2018 08:00 am ET
Molecular Templates to Present at the Ladenburg Thalmann and Cantor Healthcare Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Sep 25, 2018 04:30 pm ET
Molecular Templates, Inc. Announces Closing of Public Offering of Common Stock and the Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Sep 20, 2018 08:41 pm ET
Molecular Templates, Inc. Announces Pricing of Public Offering of Common Stock
Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Sep 19, 2018 04:01 pm ET
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic...
Sep 19, 2018 08:00 am ET
Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy
Molecular Templates, Inc. (Nasdaq:MTEM) today announced an agreement with Takeda Pharmaceutical Company Limited (Takeda) for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as...
Aug 16, 2018 07:40 am ET
Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, a
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quanex Building Products Corporation (NYSE:NX), Molecular Templates Inc....
Aug 09, 2018 04:30 pm ET
Molecular Templates, Inc. Reports Second Quarter 2018 Financial Results
Molecular Templates, Inc. (Nasdaq:MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Jun 21, 2018 04:30 pm ET
Molecular Templates Set to Join the Russell 3000® and Russell Microcap® Indexes
Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in...
Jun 04, 2018 04:30 pm ET
Molecular Templates Presents Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018
Molecular Templates, Inc. (Nasdaq:MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in...
May 31, 2018 04:05 pm ET
Molecular Templates to Present at the Jefferies Global Healthcare Conference
Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
May 23, 2018 08:15 am ET
Report: Exploring Fundamental Drivers Behind Tenneco, RadNet, Data I/O, Icahn Enterprises, PBF Logistics LP, and Molecular Templates — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tenneco Inc. (NYSE:TEN), RadNet, Inc. (NASDAQ:RDNT), Data I/O Corporation...
May 16, 2018 05:00 pm ET
Molecular Templates to Present Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018
Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in...
May 15, 2018 04:30 pm ET
Molecular Templates to Present at the UBS Global Healthcare Conference
Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
May 14, 2018 04:30 pm ET
Molecular Templates, Inc. Reports First Quarter 2018 Financial Results
Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
Mar 30, 2018 08:25 am ET
Consolidated Research: 2018 Summary Expectations for RadNet, Molecular Templates, Federated Investors, Kadant, Heartland Financial, and Calyxt — Fundamental Analysis, Key Performance Indications
NEW YORK, March 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RadNet, Inc. (NASDAQ:RDNT), Molecular Templates Inc....
Mar 28, 2018 04:30 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2017 Financial Results
Update on MT-3724 Provided at World ADC Conference; More Data Expected in 2Q18
Mar 19, 2018 04:01 pm ET
Molecular Templates to Present at the Oppenheimer 28th Annual Healthcare Conference
AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Mar 15, 2018 08:00 am ET
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2018
Presentations will feature data on 1) the company’s Antigen Seeding Technology (AST) platform, and 2) MT-5111, an Engineered Toxin Body with a novel MOA against HER2 positive cancers
Mar 08, 2018 08:00 am ET
Molecular Templates to Present at the Cowen and Company 38th Annual Health Care Conference
AUSTIN, Texas, March 08, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Mar 02, 2018 04:30 pm ET
Molecular Templates Closes $10 Million Debt Facility with Perceptive Advisors
AUSTIN, Texas, March 02, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Jan 30, 2018 07:45 am ET
New Research: Key Drivers of Growth for Fidus Investment, Athenex, Threshold Pharmaceuticals, Cintas, GNC, and Hillenbrand — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fidus Investment Corporation (NASDAQ:FDUS), Athenex, Inc....
Jan 05, 2018 08:00 am ET
Molecular Templates Provides Corporate Update and Outlines 2018 Milestones
Takeda Nominated Two Targets Under Research Collaboration in Dec. 2017
Nov 21, 2017 04:01 pm ET
Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Nov 14, 2017 04:15 pm ET
Nov 14, 2017 04:01 pm ET
Molecular Templates, Inc. Reports Third Quarter 2017 Financial Results
Completed Merger with Threshold Pharmaceuticals in August
Aug 14, 2017 08:00 am ET
Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference
AUSTIN, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the 2017 Wedbush PacGrow Healthcare Conference, taking place August 15-16 at the Le Parker Meridien hotel in New York City....